APRICOT: Recruitment Target Met!
PLUM Study still recruiting
This Phase IV trial is comparing the IL-1 receptor antagonist anakinra with placebo for the treatment of palmo-plantar pustulosis. It has recruited it's 64th and final patient into the study. This means that the Apricot team have reached their recruitment target!
A huge thank you goes out to all of the APRICOT teams for the continued support and hard work. The dedication to this study has enabled the success of the study and to arrive at this fantastic stage is amazing.
The Open Label Extension (OLE) to APRICOT has also been rolled out across many sites in the UK and there are numerous trial patients that are on, or have completed, OLE treatment.
Though recruitment has ended for APRICOT, it has a non-interventional sister study called the PLUM Study, which is still open for recruitment.
PLUM is an observational study that aims to elucidate the pathogenic mechanisms underlying pustular psoriasis, through genetic and functional investigations.
We are looking to open additional PLUM sites, so please get in touch if you are interested by contacting email@example.com. If you would like more information about the PLUM Study, please check out the PLUM page on the APRICOT website (http://apricot-trial.com/) for further study news and information.
Posted on Thursday 20th February 2020